Skip to main content
Premium Trial:

Request an Annual Quote

Genematrix HPV Detection Test Nabs CE Mark

NEW YORK – South Korean diagnostics firm Genematrix announced on Tuesday that its new human papillomavirus detection kit has received CE marking.

The NeoPlex HPV29 Detection kit can collectively detect 29 genotypes of HPV and simultaneously identify the virus genotype according to the risk of cervical cancer. It uses the firm's proprietary C-Tag multiplex RT-PCR technology.

An unnamed official for the company noted in a statement that "by reducing the turnaround time by more than an hour compared to existing products in the market, it is possible to obtain a same-day report in just half a day."

The firm also offers multiplex tests for COVID-19, respiratory tract infections, sexually transmitted infections, and gastrointestinal tract infections.

In May 2020, the firm's NeoPlex COVID-19 Detection Kit received Emergency Use Authorization from the US Food and Drug Administration.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.